In 3 % to 5 % of cases, lung cancer is associated with ALK rearrangement and can therefore be targeted with the ALK inhibitors crizotinib and ceritinib. While crizotinib is the standard first-line therapy, ceritinib has gained approval for use with patients who are crizotinib-refractory. Ceritinib showed clinical activity in both crizotinib-pretreated and ALK-inhibitor-naïve patients in the single-arm, multicentre, phase II, ASCEND-2 and ASCEND-3 studies [1, 2].
03.02.2016 | Onkologie | Online-Artikel